US drugmaker Pfizer shelves split plan

US drugmaker Pfizer, which has been considering a split into two companies for more than two years, said yesterday it will not do so because the move would not create any shareholder value.

Pfizer will keep its low-growth generics and patent-protected branded medicines separate, giving it the option to split down the road if “factors materially change at some point in the future.”

Pfizer said the decision would not have an impact on its 2016 financial forecast.